Is Supernus Pharmaceuticals Inc halal to invest in?

As of July 2026, Supernus Pharmaceuticals Inc SUPN is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Supernus Pharmaceuticals Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Supernus Pharmaceuticals Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Supernus Pharmaceuticals Inc?

Muslim investors may consider investing in Supernus Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Supernus Pharmaceuticals Inc classified as HALAL?

Musaffa determines the Shariah status of Supernus Pharmaceuticals Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Supernus Pharmaceuticals Inc updated?

The Shariah compliance status of Supernus Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Supernus Pharmaceuticals Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Supernus Pharmaceuticals Inc?

You can check the latest Shariah compliance status of Supernus Pharmaceuticals Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

SUPN Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Supernus Pharmaceuticals Inc is classified as halal.

HALAL

Report Source: 2026 1st Quarter Report

Supernus Pharmaceuticals Inc. Stock Analysis SUPN

United States Health Care Mid Cap Report: Q1, 2026

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 778 full-time employees. The company went IPO on 2010-12-28. The company focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its neuroscience portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Its products include Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, ONAPGO, XADAGO, and MYOBLOC. Qelbree is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older. GOCOVRI extended-release capsules are medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy. The company is also involved in developing product candidates in neurology and psychiatry, including SPN-817 (huperzine A), SPN-820 (NV-5138), and SPN-443.

Key Statistics of Supernus Pharmaceuticals Inc (SUPN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$47.18$48.13

Today's Open

$47.87

Volume

618.82K

P/E Ratio (TTM)

52 Week Range

$32.20$59.68

Market Cap

2.93B

Avg. Volume

914.58K

Dividend Yield

Financial Metrics & Statements of Supernus Pharmaceuticals Inc (SUPN)

Super Investors Invested in Supernus Pharmaceuticals Inc (SUPN)

FAQ's for Supernus Pharmaceuticals Inc (SUPN)

As of July 2026, Supernus Pharmaceuticals Inc SUPN is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Supernus Pharmaceuticals Inc using these criteria to determine its compliance status.
Muslim investors may consider investing in Supernus Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of Supernus Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of Supernus Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of Supernus Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.